Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thimerosal-Autism Potential Link Will Be Examined In Two CDC Studies

Executive Summary

The Centers for Disease Control & Prevention is planning two studies to determine if there is a link between mercury in vaccines and neurodevelopment disorders in children

You may also be interested in...

Are Vaccines Linked To Autism? VICP Will Decide On Causation By July 2004

The Vaccine Injury Compensation Program expects a court decision on whether vaccines cause autism by July 2004, Department of Justice Civil Division Senior Counsel Torts Branch Gabrielle Manginiello told an Advisory Commission on Childhood Vaccines conference call Sept. 4

Thimerosal-Free Flu Vaccine Design Being Discussed By FDA, Manufacturers

FDA is discussing with manufacturers the development of influenza vaccines that have reduced thimerosal content or are thimerosal-free.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts